Serogroup B meningococcal vaccines

Current Opinion in Investigational Drugs

Volumn 7, Issue 8, 2006, Pages 733-739

  Zimmer, Shanta M ^a,b   Stephens, David S ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Hexavalent; Monovalent; Serogroup B Neisseria meningitidis; Vaccine

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEXAMEN; MENINGOCOCCUS VACCINE; MONOMEN; NONAMEN; OUTER MEMBRANE VESICLE VACCINE; POLYSACCHARIDE VACCINE; TOLL LIKE RECEPTOR 4; TRANSFERRIN BINDING PROTEIN; UNCLASSIFIED DRUG; VA MENGOC BC; VIRUS VACCINE;

AGE DISTRIBUTION; BLOOD GROUP TYPING; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; ENDEMIC DISEASE; EPIDEMIC; EPIDEMIC MENINGITIS; EUROPE; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; IMMUNOPATHOGENESIS; INCIDENCE; MORTALITY; NEISSERIA MENINGITIDIS; NEISSERIACEAE INFECTION; NEW ZEALAND; NONHUMAN; PREVALENCE; PROTEIN TARGETING; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; STANDARDIZATION; STATISTICAL SIGNIFICANCE; UNITED STATES; VIRAL GENETICS; VIRUS PATHOGENESIS; VIRUS STRAIN; VIRUS VIRULENCE;

HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS;

EID: 33747621161     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Raghunathan PL, Bernhardt SA, Rosenstein NE: Opportunities for control of meningococcal disease in the United States. Annu Rev Med (2004) 65:333-353.
2. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM: Meningococcal disease. N Engl J Med (2001) 344(18):1378-1388.
3. Pollard AJ, Scheifele D: Meningococcal disease and vaccination in North America. J Paediatr Child Health (2001) 37(5): S20-S27.
4. Racoosin JA, Whitney CG, Conover CS, Diaz PS: Serogroup Y meningococcal disease in Chicago, 1991-1997. J Am Med Assoc (1998) 280(24):2094-2098.
5. Miller MA, Wenger J, Rosenstein N, Perkins B: Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa. Pediatr Infect Dis J (1999) 18(12):1051-1059.
6. Robbins JB, Towne DVV, Gotschlich EC, Schneerson R: 'Love's labours lost': Failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet (1997) 350(9081):880-882.
7. Wider-Smith A, Goh KT, Barkham T, Paton NI: Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: Estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis (2003) 36(6):679-683.
8. Decosas J, Koama JB: Chronicle of an outbreak foretold: Meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis (2002) 2(12):763-765.
9. Nakhla I, Frenck RW Jr, Teleb NA, Oun SE, Sultan Y, Mansour H, Mahoney F: The changing epidemiology of meningococcal meningitis after introduction of bivalent A/C polysaccharide vaccine into school-based vaccination programs in Egypt. Vaccine (2005) 23(25):3288-3293.
10. Gaspar M, Leite F, Brumana L, Felix B, Stella AA: Epidemiology of maningococcal meningitis in Angola, 1994-2000. Epidemiol Infect (2001) 127(3):421-424.
11. Pollard AJ: Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J (2004) 23(12 Suppl):S274-S279.
12. Trotter CL, Ramsay ME, Kaczmarski EB: Meningococcal serogroup C conjugate vaccination in England and Wales: Coverage and initial impact of the campaign. Commun Dis Public Health (2002) 5(3):220-225.
13. Baker MG, Martin DR, Kieft CE, Lennon D: A 10-year serogroup B meningococcal disease epidemic in New Zealand: Descriptive epidemiology, 1991-2000. J Paediatr Child Health (2001) 37(6):S13-S19.
14. Sierra GV, Camps HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, Casanueva GV, Pico CO, Rodriguez CR, Terry MH: Vaccine against group B Neisseria meningitidis. Protection trial and mass vaccination results in Cuba. NIPH Ann (1991) 14(2):195-207.
15. Zollinger WD, Boslego J, Moran E, Garcia J, Cruz C, Ruiz S, Brandt B, Martinez M, Arthur J, Underwood P et al: Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. The Chilean National Committee for Meningococcal Disease. NIPH Ann (1991) 14(2):211-212.
16. de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, Landgraf IM, Gattas VL, Vasconcelos Hde G et al: Protective efficacy of a serogroup 8 meningococcal vaccine in Sao Paulo, Brazil. Lancet (1992) 340(8827):1074-1078.
17. Bjune G, Hoiby EA, Gronnesby JK Amesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nokleby H, Rosenqvist E. et al: Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet (1991) 338(8775):1093-1096.
18. Peltola H, Jonsdottir K, Lystad A, Sievers CJ, Kallings I: Meningococcal disease in Scandinavia. Br Med J (Clin Res Ed) (1982) 284(6329):1618-1621.
19. Kahler CM, Stephens DS: Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin). Crit Rev Microbiol (1998) 24(4):281-334.
20. Morley SL, Pollard AJ: Vaccine prevention of meningococcal disease, coming soon? Vaccine (2001) 20(5-6):666-687.
21. Swartley JS, Martin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, Wenger JD, Stephens DS: Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA (1997) 94(1):271-276.
22. Eisen DP, Minchinton RM: Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis (2003) 37(11):1496-1505.
23. Meningococcal disease prevention and control strategies for practice-based physicians (Addendum: Recommendations for college students). Committee on Infectious Diseases. Pediatrics (2000) 106(6):1500-1504.
24. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C: Prevention of maningococcal disease by group C polysaccharide vaccine. N Engl J Med (1970) 282(8):417-420.
25. Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC: Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest (1975) 56(6):1536-1547.
26. Lepow ML, Beeler J, Randolph M, Samuelson JS, Hankins WA: Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J infect Dis (1986) 154(6):1033-1036.
27. Goldschneider I, Lepow ML, Gotschlich EC: Immunogenicity of the group A and group C meningococcal polysaccharides in children. J Infect Dis (1972) 125(5):509-519.
28. MacDonald NE, Halperin SA, Law BJ, Danzig LE, Granoff DM: Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine? J Am Med Assoc (2000) 283(14):1826-1827.
29. Artenstein MS, Brandt BL: Immunologic hyporesponsiveness in man to group C meningococcal polysaccharide. J Immunol (1975) 115(1):5-7.
30. Larrauri A, Cano R, Garcia M, Mateo S: Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine (2005) 23(32):4097-4100.
31. Cano R, Larrauri A, Mateo S, Alcala B, Salcedo C, Vazquez JA: Impact of the meningococcal C conjugate vaccine in Spain: An epidemiological and microbiological decision. Euro Surveill (2004) 9(7):11-15.
32. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME: Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet (2004) 364(9431):365-367.
33. Maiden MC, Stuart JM: Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet (2002) 359(9320):1829-1831.
34. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E: Herd immunity from meningococcal serogroup C conjugate vaccination in England: Database analysis. Br Med J (2003) 326(7385):365-366.
35. Bilukha OO, Rosenstein N: Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2005) 54(RR-7):1-21.
36. Finne J, Leinonen M, Makela PH: Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet (1983) 2(8346):355-357.
37. Griffiss JM, Yamasaki R, Estabrook M, Kim JJ: Meningococcal molecular mimicry and the search for an ideal vaccine. Trans R Soc Trop Med Hyg (1991) 85(Suppl 1):32-36.
38. Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D: Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult male volunteers. Vaccine (2004) 22(9-10):1087-1096.
39. Moe GR, Dave A, Granoff DM: Molecular analysis of anti-N-propionyl Neiesseria meningitidis group B polysaccharide monoclonal antibodies. Mol Immunol (2006) 43(9):1424-1431.
40. Moe GR, Dave A, Granoff DM: Epitopes recognized by a nonautoreactive, murine anti-N-propionyl meningococcal group B polysaccharide monoclonal antibody. Infect Immun (2005) 73(4):2123-2128.
41. Bjune G, Gronnesby JK, Hoiby EA, Closs O, Nokleby H: Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann (1991) 14(2):125-130.
42. Tappero JVV, Lagos P, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Hoiby EA, Holst J, Nokleby H et al: Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile. J Am Med Assoc (1999) 281(16):1520-1527.
43. Milagres LG, Ramos SR, Sacchi CT, Melles CE, Vieira VS, Sato H, Brito GS, Morass JC, Frasch CE: Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: Comparison with efficacy. Infect Immun (1994) 62(10):4419-4424.
44. Perkins BA, Jonsdottir K, Briem H, Griffiths E, Plikaytis BD, Hoiby EA, Rosenqvist E, Holst J, Nokleby H, Sotolongo F, Sierra G et al: Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis (1998) 177(3):683-691.
45. Morley SL, Cole MJ, Ison CA, Camaraza MA, Sotolongo F, Anwar N, Cuevas I, Carbonero M, Campa HC, Sierra G, Levin M: Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis, strains in infants. Pediatr Infect Dis J (2001) 20(11):1054-1061.
46. Wedege E, Kuipers B, Bolstad K, van Dijken H, Froholm LO, Vermont C, Caugant DA, van den Dobbelsteen G: Antibody specificities and effect of meningococcal carriage in Icelandic teenagers receiving the Norwegian serogroup, B outer membrane vesicle vaccine. Infect Immun (2003) 71(7):3775-3781.
47. Ameratunga S, Macmillan A, Stewart J, Scott D, Mulholland K, Crengie S: Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: A multi-faceted strategy. Vaccine (2005) 23(17-18):2231-2234.
48. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D: MeNZB: A safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine (2005) 23(17-18):2191-2196.
49. de Kleijn ED, de Groot R, Lafeber AB, Labadie J, van Limpt CJ, Visser J, Berbers GA, van Alphen L, Rumke HC: Prevention of meningococcal serogroup B infections in children: A protein-based vaccine induces immunologic memory. J Infect Dis (2001) 184(1):98-102.
50. Vermont CL, van Dijken, HH, Kuipers AJ, van Limpt CJ, Keijzers WC, van der Ende A, de Groot R, van Alphen L, van den Dobbelsteen GP: Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine. Infect Immun (2003) 71(4):1650-1655.
51. Cartwright K, Morris R, Rumke H, Fox A, Borrow R, Begg N, Richmond P, Poolman J: Immunogenicity and reactogenicity in UK infants of a novel meningocooccal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine (1999) 17(20-21):2612-2619.
52. Vermont CL, van den Dobbelsteen GP, de Groot R: Recent developments in vaccines to prevent maningococcal serogroup B infections. Curr Opin Mol Ther (2003) 5(1):33-38.
53. Findlow J, Lowe A, Deane S, Balmer P, van den Dobbelsteen G, Dawson M, Andrews N, Borrow R: Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children. Vaccine (2005) 23(20):2623-2627.
54. Sacchi CT, Lemos AP, Popovic T, De Morais JC, Whitney AM, Melles CE, Brondi LM, Monteiro LM, Paiva MV, Solari CA, Mayer LW: Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997-1998: Overview and implications for vaccine development. J Clin Mirobiol (2001) 39(8):2897-2903.
55. Van Alphen L: Multivalent meningococcal B OMV vaccines. Serogroup S Meningococcal Vaccines Meeting, Atlanta, GA USA (2005).
56. Boslego J, Garcia J, Cruz C, Zollinger W, Brandt B, Ruiz S, Martinez M, Arthur J, Underwood P, Silva W, Moran E et al: Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine (1995) 13(9):821-829.
57. Tondella ML, Popovic T, Rosenstein NE, Lake DB, Carlone GM, Mayer LW, Perkins BA: Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol (2000) 38(9):3323-3328.
58. Ahonkhai VI, Lukacs LJ, Jonas LC, Calandra GB: Clinical experience with PedvaxHIB, a conjugate vaccine of Haemophilus influenzae type 8 polysaccharide-Neisseria meningitidis outer membrane protein. Vaccine (1991) 9(Suppl):S38-S41.
59. Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, Eisen JA, Ketchum KA, Hood DW, Peden JF, Dodson RJ, Nelson WC et al: Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science (2000) 287(5459):1809-1815.
60. Masignani V, Rappuoli R, Pizza M: Reverse vaccinology: A genome-based approach for vaccine development. Expert Opin Biol Ther (2002) 2(8):895-905.
61. Kelly DF, Rappuoli R: Reverse vaccinollogy and vaccines for serogroup B Neisseria meningitidis. Adv Exp Med Biol (2005) 568:217-223.
62. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, Galeotti CL et al: Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (2000) 287(5459):1816-1820.
63. Martin D, Brodeur BR, Hamel J, Couture F, de Alwis U, Lian Z, Martin S, Andrews D, Ellis RW. Candidate Neisseria meningitidis NspA vaccine. J Biotechnol (2000) 83(1-2):27-31.
64. Martin D, Cadieux N, Hamel J, Brodeur BR: Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med (1997) 185(7):1173-1183.
65. Moe GR, Zuno-Mitchell P, Lee SS, Lucas AH, Granoff DM: Functional activity of anti-neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Infect Immun (2001) 69(6):3762-3771.
66. Moe GR, Tan S, Granoff DM: Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun (1999) 67(11):5664-5675.
67. Jacobsson S, Thulin S, Molling P, Unemo M, Comanducci M, Rappuoli R, Olcen P: Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine (2005) 24(12):2161-2168.
68. Oomen CJ, Hoogerthout P, Kuipers B, Vidarsson G, van Alphen L, Gros P: Crystal structure of an anti-meningococcal subtype P1.4 PorA antibody provides basis for peptide-vaccine design. J Mol Biol (2005) 351(5):1070-1080.
69. Rokbi B, Renauld-Mongenie G, Mignon M, Danve B, Poncet D, Chabanel C, Caugant DA, Quentin-Millet MJ: Allelic diversity of the two transferrin binding protein B gene isotypes among a collection of Neisseria meningitidis strains representative of serogroup B disease: Implication for the composition of a recombinant TbpB-based vaccine. Infect Immun (2000) 68(9):4938-4947.
70. Sun Y, Li Y, Exley RM, Winterbotham M, Ison C, Smith H, Tang CM: Identification of novel antigens that protect against systemic meningococcal infection. Vaccine (2005) 23(32):4136-4141.
71. Wright JC, Williams JN, Christodoulides M, Heckels JE: Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis. Infect Immun (2002) 70(8):4028-4034.
72. Jessouroun E, da Silveira IF, Larangeira AP, Pereira S, Fernandes SA, Rabinovitch L, Frasch CE, Castro-Faria-Neto HC, Bozza PT: Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock. Vaccine (2004) 22(20):2617-2625.
73. Uronen-Hansson H, Steeghs L, Allen J, Dixon GL, Osman M, van der Ley P, Wong SY, Callard R, Klein N: Human dendritic cell activation by Neisseria meningitidis: Phagocytosis depends on expression of lipooligosaccharide (LOS) by the bacteria and is required for optimal cytokine production. Cell Microbiol (2004) 6(7):625-637.
74. Ala'Aldeen DA, Stevenson P, Griffiths E, Gorringe AR, Irons LI, Robinson A, Hyde S, Borriello SP: Immune responses in humans and animals to meningococcal transferrin-binding proteins: Implications for vaccine design. Infect Immun (1994) 62(7):2984-2990.
75. Danve B, Lissolo L, Mignon M, Dumas P, Colombani S, Schryvers AB, Quentin-Millet MJ: Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine (1993) 11(12):1214-1220.
76. Johnson AS, Gorringe AR, Fox AJ, Borrow R, Robinson A: Analysis of the human Ig isotype response to individual transferrin binding proteins A and B from Neisseria meningitidis. FEMS Immunol Med Microbiol (1997) 19(2):159-167.
77. 2-glycosylation determine the specific immunostimulatory activity of Neisseria meningitidis lipid A for human monocyte derived dendritic cells. Vaccine (2005) 24(9):1291-1297.
78. Rodriguez T, Perez O, Menager N, Ugrinovic S, Bracho G, Mastroeni P: Interactions of proteoliposomes from serogroup B Neisseria meningitidis with bone marrow-derived dendritic: cells and macrophages: Adjuvant effects and antigen delivery. Vaccine (2005) 23(10):1312-1321.
79. Dixon GL, Newton PJ, Chain BM, Katz D, Andersen SR, Wong S, van der Ley P, Klein N, Callard RE: Dendritic cell activation and cytokine production induced by group B Neisseria meningitidis: Interleukin-12 production depends on lipopolysaccharide expression in intact bacteria. Infect Immun (2001) 69(7):4351-4357.
80. Sun YY, Hu XJ: Preparation and immunogenicity of serogroup B meningococcal OS-OMPC conjugates. Biomed Environ Sci (1999) 12(4):298-303.
81. Aase A, Naess LM, Sandin RH, Herstad TK, Oftung F, Holst J, Haugen IL, Hoiby EA, Michaelsen TE: Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine (2003) 21(17-18):2042-2051.
82. Bowe F, Lavelle EC, McNeela EA, Hale C, Clare S, Arico B, Giuliani MM, Rae A, Huett A, Rappuoli R, Dougan G, Mills KH: Mucosal vaccination against serogroup B meningococci: Induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enteratoxin. Infect Immun (2004) 72(7):4052-4060.
83. Goldschneider I, Gotschlich EC, Artenstein MS: Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med (1969) 129(6):1307-1326.
84. Borrow R, Balmer P, Miller E: Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine (2005) 23(17-18):2222-2227.
85. Chippaux JP, Garba A, Ethevenaux C, Campagne G, de Chabalier F, Djibo S, Nicolas P, Ali H, Charrondiere M, Ryall R, Bybel M, Schuchat A: Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger. Vaccine (2004) 22(25-26):3303-3311.
86. Andrews N, Borrow R, Miller E: Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol (2003) 10(5):780-786.
87. Holst J, Feiring B, Fuglesang JE, Hoiby EA, Nokleby H, Aaberge IS, Rosenqvist E: Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Naisseria meningitidis, serogroup B disease. Vaccine (2003) 21(7-8):734-737.
88. Vicente D, Esnal O, Michaus L, Lopez de Goicoechea MJ, Cistema, R, Perez-Trallero E: Prevalence of genosubtypes (PorA types) of serogroup B invasive meningococcus in the north of Spain from 2000 to 2003. J Med Microbiol (2005) 54(4):381-384.
89. Sacchi CT, Whitney AM, Popovic T, Beall DS, Reeves MW, PlikaytiS BD, Rosenstein NE, Perkins BA, Tondella MI, Mayer LW: Diversity and prevalence of PorA types in Neisseria meningitidis serogroup, B in the United States, 1992-1998. J Infect Dis (2000) 182(4):1169-1176.
90. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, Arhin FF, Devi SJ, Frasch CE, Huang JC, Kriz-Kuzemenska P et al: Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab immunol (1997) 4(2):156-167.
91. Vermont C, van den Dobbelsteen G: Neisseria meningitidis serogroup B: Laboratory correlates of protection. FEMS Immunol Med Microbiol (2002) 34(2):89-96.